Riskpilot← Back to searchSign inGet full accessZP GENERAL PARTNER 2 ApS
APSActiveCVR 36407344Sydmarken 11Research and experimental development on natural sciences and engineering · NACE 7210Est. 2014— employees
Revenue 2025
DKK 5K
+150% vs 2024
EBITDA margin
-360.0%
-38% vs 2024
Equity ratio
70.2%
Financial strength
Net profit 2025
DKK -22K
-37% vs 2024
| Revenue | DKK 5K | +150% |
| EBITDA | DKK -18K | -38% |
| Net profit | DKK -22K | -37% |
| Total assets | DKK 114K | +111% |
| Equity | DKK 80K | +129% |
| Employees | — | — |
Legal name
ZP GENERAL PARTNER 2 ApS
CVR number
36407344
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
15. oktober 2014
Share capital
DKK 90.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to direktører i forening.
Company purpose
Selskabets formål er at være komplementar i ZP SPV 1 K/S.
Address
Sydmarken 11
Email
info@zealandpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | — | — | — | — | 6 | 1 | 4 | 4 | 2 | 5 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 0 | -0 | -0 | -2 | -1 | -0 | 5 | -1 | -11 | -9 | -13 | -18 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 0 | -0 | -0 | -2 | -1 | -0 | 5 | -1 | -11 | -9 | -13 | -18 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -3 | -3 | -4 |
| Profit before tax | 0 | -0 | -0 | -2 | -1 | -0 | 5 | -1 | -13 | -12 | -16 | -22 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | 1 | -0 | -0 | -0 | -0 | -0 |
| Net profit | 0 | -0 | -0 | -2 | -1 | -0 | 4 | -1 | -13 | -12 | -16 | -22 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 0 | 0 | 0 | 6 | 3 | 0 | 31 | 16 | 172 | 63 | 54 | 114 |
| Equity | 0 | 0 | 0 | 3 | 2 | 0 | 25 | 12 | 63 | 51 | 35 | 80 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 3 | 1 | 0 | 6 | 4 | 109 | 12 | 19 | 34 |
| Total debt | 0 | 0 | 0 | 3 | 1 | 0 | 6 | 4 | 109 | 12 | 19 | 34 |
EBITDA margin
-360.0%
This company
15.8%
Market median
-2378% vs market
20142025
Equity ratio
70.2%
This company
38.2%
Market median
+84% vs market
20142025
Return on equity
-27.5%
This company
18.4%
Market median
-249% vs market
20142025
Net profit margin
-440.0%
This company
8.1%
Market median
-5532% vs market
20142025
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
20142025
Debt / equity
0.42×
This company
0.62×
Market median
+32% vs market
20142025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-10-15 – 2014-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MD Management | Management | 2019 | — | — |
MP Management | Management | 2014 | — | — |
DH Management | Management | 2014 | — | — |
ED Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
AS Management | Management | 2022 | — | — |
IM Management | Management | 2019 | — | — |
HW Management | Management | 2022 | — | — |
ED Management | Management | 2019 | — | — |
BM Management | Management | 2015 | — | — |
LR Management | Management | 2022 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ZP HOLDING SPV K/S | Company | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ZEALAND PHARMA A/S
ZP GENERAL PARTNER 2 ApS Board members of ZP GENERAL PARTNER 2 ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Matthew Donald Dallas | Management | 0 companies |
| Mats Peter Blom | Management | 0 companies |
| David Horn Solomon | Management | 0 companies |
| Emmanuel Dulac | Chief Executive Officer | 0 companies |
| Adam Sinding Steensberg | Management | 0 companies |
| Ivan Mourits Møller | Management | 0 companies |
| Henriette Wennicke | Management | 0 companies |
| Emmanuel Dulac | Management | 0 companies |
| Britt Meelby Jensen | Management | 0 companies |
| Lykke Rømer | Management | 0 companies |